Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant
to the treatment of cardiovascular diseases. These endogenous vesicles have certain …

The response of immune cells in cardiac injury is divided into three continuous phases:
inflammation, proliferation and maturation. The kinetics of the inflammatory and proliferation …

The adult mammalian heart is non-regenerative owing to the post-mitotic nature of
cardiomyocytes. The neonatal mouse heart can regenerate, but only during the first week of …

Medicine relies on the use of pharmacologically active agents (drugs) to manage and treat
disease. However, drugs are not inherently effective; the benefit of a drug is directly related …

Stem cell therapy is a promising therapeutic method for the treatment of ischemic heart
diseases; however, some challenges prohibit the efficacy after cell delivery due to hostile …

Mesenchymal stem cells (MSCs) have been widely studied as a versatile cell source for
tissue regeneration and remodeling due to their potent bioactivity, which includes …

Heart disease remains a major cause of death despite advances in medical technology.
Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising …

In the tissue engineering (TE) paradigm, engineering and life sciences tools are combined
to develop bioartificial substitutes for organs and tissues, which can in turn be applied in …

The reprogramming of adult cells into pluripotent cells or directly into alternative adult cell
types holds great promise for regenerative medicine. We reported previously that cardiac …

Heart failure plagues industrialized nations, killing more people than any other disease. It
usually results from a deficiency of specialized cardiac muscle cells known as …